Literature DB >> 3459393

The presence of desulfo xanthine dehydrogenase in purified and crude enzyme preparations from rat liver.

T Ikegami, T Nishino.   

Abstract

Crude and purified xanthine dehydrogenase preparations from rat liver were examined for the existence of a naturally occurring inactive form. Reduction of the purified enzyme by xanthine under anaerobic conditions proceeded in two phases. The enzyme was inactivated by cyanide, which caused the release of a sulfur atom from the molybdenum center as thiocyanate. The amount of thiocyanate released was almost in parallel with the initial specific activity. The active and inactive enzymes could be resolved by affinity chromatography on Sepharose 4B/folate gel. These results provided evidence that the purified enzyme preparation from rat liver contained an inactive form. A method for the determination of the active and inactive enzymes in crude enzyme preparations from rat liver was devised based on the fact that only active enzyme could react with [14C]allopurinol and both active and inactive enzymes could be immunoprecipitated quantitatively by excess specific antibody to xanthine dehydrogenase. The amount of [14C]alloxanthine (derived from [14C]allopurinol) bound to the active sulfo enzyme in crude rat liver extracts was about 0.5 mol/mol of FAD. As this content is closely similar to that in the purified enzyme, these results suggest the existence of an inactive desulfo form in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459393     DOI: 10.1016/0003-9861(86)90582-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

Review 1.  A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase.

Authors:  A Kooij
Journal:  Histochem J       Date:  1994-12

2.  The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase.

Authors:  Tomoko Nishino; Ken Okamoto; Yuko Kawaguchi; Tomohiro Matsumura; Bryan T Eger; Emil F Pai; Takeshi Nishino
Journal:  FEBS J       Date:  2015-04-13       Impact factor: 5.542

3.  Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury.

Authors:  Takashi Tani; Ken Okamoto; Megumi Fujiwara; Akira Katayama; Shuichi Tsuruoka
Journal:  Mol Med       Date:  2019-08-22       Impact factor: 6.354

Review 4.  Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.

Authors:  Kimiyoshi Ichida; Yoshihiro Amaya; Ken Okamoto; Takeshi Nishino
Journal:  Int J Mol Sci       Date:  2012-11-21       Impact factor: 5.923

5.  Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues.

Authors:  R F Anderson; K B Patel; K Reghebi; S A Hill
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

6.  Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth.

Authors:  Teruo Kusano; Driss Ehirchiou; Tomohiro Matsumura; Veronique Chobaz; Sonia Nasi; Mariela Castelblanco; Alexander So; Christine Lavanchy; Hans Acha-Orbea; Takeshi Nishino; Ken Okamoto; Nathalie Busso
Journal:  Nat Commun       Date:  2019-10-28       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.